Synonyms: Heartgard® | ivermectin B1a | MK-933 | Sklice® | Soolantra®
ivermectin is an approved drug (FDA (1996), UK (2015))
Compound class:
Synthetic organic
Comment: Ivermectin is a broad-spectrum anti-parasitic drug. The approved drug is a mixture of mainly avermectin H2B1a (CAS # 71827-03-7) with some avermectin H2B1b (CAS # 70209-81-3). The avermectins are bacterial marcrolides isolated from Streptomyces avermitilis.
SARS-CoV-2 and COVID-19: There is speculation that ivermectin could be used to treat COVID-19, which is principally founded on in vitro evidence of anti-viral activity, and limited evidence of anti-inflammatory action. The evidence that ivermectin is appropriate to prevent or treat coronavirus infection is not compelling. To date (Jan 2021) there is no persuasive efficacy data available from an adequately sized, appropriately designed and controlled randomised clinical trial. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Used in the treatment of parasitic infections (excluding tapeworm), and as a topical treatment for head lice. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |